In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model.
In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model.
复制标题
DOI：
10.1097/rli.0b013e31819f1b60
复制
发表时间：
2009-05
影响因子：
6.7
通讯作者：
Yeh BM
中科院分区：
文献类型：
--
作者：
Raatschen HJ;Fu Y;Brasch RC;Pietsch H;Shames DM;Yeh BM
To evaluate the potential of dynamic CT enhanced by Iohexol or a novel macromolecular contrast agent, PEG12000-Gen4-triiodo, to monitor microvascular changes in tumors treated with the angiogenesis inhibitor bevacizumab. Ten female nude rats with MDA-MB 435 xenograft tumors were treated with 1 mg intraperitoneal bevacizumab when tumors reached 1 cm diameter and, for 4 rats, treated again 7 days later. Just prior to and 24 hours after the first injection of anti-VEGF antibody, the tumors were imaged by dynamic CT scans enhanced with PEG12000-Gen4-triiodo [n=3 rats] or Iohexol [n=3 rats]. The other 4 rats underwent dynamic CT scans enhanced with PEG12000-Gen4-triiodo just prior to and 24 hours after the second injection of anti-VEGF antibody. Microvascular leakiness (KPS) was calculated for the tumors using a two-compartment tissue model. PEG12000-Gen4-triiodo-enhanced CT scans showed progressive reductions in KPS from Day 1 to 2 to 9 (from 2.55 to 1.27 to 0.69 μl min−1 cm−3, respectively, p < 0.005 for each comparison of Day 1 to 2, and Day 2 to 9). No significant difference was seen in the KPS estimates derived from Iohexol-enhanced CT scans obtained before or after treatment (276 versus 223.8 μl min−1cm−3, respectively, p = 0.54). The microvascular leak (KPS) was significantly larger for Iohexol than for PEG12000-Gen4-triiodo-enhanced CT, p<0.05. Dynamic macromolecular contrast-enhanced CT can be used to monitor serial decreases in tumor microvessel leakiness induced by repeated doses of an angiogenesis inhibitor drug
